

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 532212002000

Application Number 10/664,263

Applicant

Thomas L. CANTOR

Filing Date September 16, 2003

Group Art Unit: 1641

Mailing Date January 22, 2004



COPY

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	01/2002	20020009740	Kaddurah-Daouk et al.	435	6	
	2.	02/2003	20030040027	Ritter et al.	435	7.21	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Ben Ghanem et al, Hybridoma 12(5):599-608 (1993)
	4.	Dybedal et al., Blood 86(3):949-57 (1995)
	5.	Eckardt et al., Nephrol. Dial. Transplant 18:865-69 (2003)
	6.	EPOGEN® (Epoetin alfa) (available on the internet at <a href="http://www.renaladvances.com/PDF/EpogenPI.pdf">www.renaladvances.com/PDF/EpogenPI.pdf</a> ) product insert
	7.	Eschbach et al., N. Engl. J. Med. 316:73-78 (1987)
	8.	Goodman et al., Adv. Ren. Replace Ther. 2002 Jul;9(3):200-8
	9.	Hillman, Hematopoietic Agents - Growth Factors, Minerals, and Vitamins, in THE PHARMACOLOGICAL BASIS OF THERAPEUTICS 1312-15 (JG Hardman, et al. eds., 9th ed. 1996)
	10. ✓	Jacobs et al., Nature 313:806 (1985)
	11.	Johnson & Johnson Press Release "Summary of PRCA Case Reports," July 14, 2003 (available at <a href="http://www.jnj.com/news/jnj_news/1021024_095632.htm">www.jnj.com/news/jnj_news/1021024_095632.htm</a> )
	12.	Kifor et al., J. Clin. Endocrinology & Metabolism 88(1):60-72 (2003)
	13. ✓	Lin et al., Proc. Natl. Acad. Sci. USA 82:7580 (1985)
	14.	Parthemore et al., J. Clin. Endocrinol. Metab. 1978 Aug;47(2):284-9
	15.	Ponnappan et al., Hybridoma 19(5):355-61 (2000)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 532212002000	Application Number 10/664,263
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <small>(Use several sheets if necessary)</small>		Applicant Thomas L. CANTOR	
		Filing Date September 16, 2003	Group Art Unit: 1641
		Mailing Date January <u>22</u> , 2004	
			
	PROCRIT® (Epoetin alfa) (available on the internet at <a href="http://healthcareprofessionals.orthobiotech.com/products/procrit/procrit.pdf">healthcareprofessionals.orthobiotech.com/products/procrit/procrit.pdf</a> ) product insert		
17.	Savvyer et al., Hematol. Oncol. Clinics NA 8:895 (1994)		
COPY			
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			